The possible role of peroxisome proliferator-activated receptor gamma in heart failure.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Experimental and Clinical Cardiology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 19641720PMCID PMC2716741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction

  2004cited by this paper
• The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor-&agr; and Receptor-&ggr; Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension

  2003cited by this paper
• Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

  2003cited by this paper
• Agonists of Peroxisome-Proliferator Activated Receptor-Gamma Reduce Renal Ischemia/Reperfusion Injury

  2003cited by this paper
• The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock.

  2003cited by this paper
• GATA-6 Is Involved in PPAR&ggr;-Mediated Activation of Differentiated Phenotype in Human Vascular Smooth Muscle Cells

  2003cited by this paper
• Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-γ, Pioglitazone

  2003cited by this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model

  2003cited by this paper
• Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

  2003cited by this paper
• Activation of Peroxisome Proliferator–Activated Receptor-&agr; Protects the Heart From Ischemia/Reperfusion Injury

  2003cited by this paper
• Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease.

  2002cited by this paper
• The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation.

  2002cited by this paper
• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  2002cited by this paper
• Ligands of the peroxisome proliferator‐activated receptors (PPAR‐γ and PPAR‐α) reduce myocardial infarct size

  2002cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

  2002cited by this paper
• Thiazolidinedione‐Induced Edema

  2002cited by this paper
• Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

  2002cited by this paper
• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.

  2002cited by this paper
• Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-γ ligand, pioglitazone, in rats

  2002cited by this paper
• PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice.

  2002cited by this paper
• Response of experimental retinal neovascularization to thiazolidinediones.

  2001cited by this paper
• Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.

  2001cited by this paper
• A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.

  2001cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cited by this paper
• Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.

  2001cited by this paper
• Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.

  2000cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

  2000cited by this paper
• Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.

  2000cited by this paper
• Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.

  2000cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

  2000cited by this paper
• PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

  2000cited by this paper
• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  2000cited by this paper
• Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.

  2000cited by this paper
• Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.

  2000cited by this paper
• Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction.

  1999cited by this paper
• Insulin resistance in patients with cardiac hypertrophy.

  1999cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

  1999cited by this paper
• Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

  1999cited by this paper
• c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity.

  1999cited by this paper
• Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.

  1999cited by this paper
• Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension.

  1999cited by this paper
• PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.

  1999cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo *

  1999cited by this paper
• Activation of PPARgamma coactivator-1 through transcription factor docking.

  1999cited by this paper
• Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.

  1998cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Nuclear Integration of Glucocorticoid Receptor and Nuclear Factor-κB Signaling by CREB-binding Protein and Steroid Receptor Coactivator-1*

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system.

  1998cited by this paper
• Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

  1998cited by this paper
• Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists*

  1997cited by this paper
• Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.

  1997cited by this paper
• The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP.

  1997cited by this paper
• p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha.

  1997cited by this paper
• CREB-binding protein/p300 are transcriptional coactivators of p65.

  1997cited by this paper
• Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients

  1997cited by this paper
• Adipogenesis and obesity: rounding out the big picture.

  1996cited by this paper
• Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma.

  1996cited by this paper
• Endothelin-1 Is Involved in Mechanical Stress-induced Cardiomyocyte Hypertrophy (*)

  1996cited by this paper
• Effect of insulin on renal sodium and uric acid handling in essential hypertension.

  1996cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha.

  1996cited by this paper
• Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

  1996cited by this paper
• Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.

  1996cited by this paper
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  1995cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

  1994cited by this paper
• Molecular mechanisms of action of steroid/thyroid receptor superfamily members.

  1994cited by this paper
• Effects of endothelins on collagen turnover in cardiac fibroblasts.

  1993cited by this paper
• Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes.

  1993cited by this paper
• Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects

  1992cited by this paper
• Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper

• Role of PPAR-related genes in chronic heart failure: evidence from large populations

  2023cites this paper
• Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy

  2022cites this paper
• Fibrosis and cardiac dysfunction in insulin-resistant rats : changes in myocardial type I collagen and telmisartan ’ s effects

  2019cites this paper
• Peroxisome proliferator-activated receptors as therapeutic targets for heart failure.

  2017cites this paper
• Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure

  2016cites this paper
• The expression receptor of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in human aorta compared to left ventricle in patients with coronary artery disease without diabetes

  2012cites this paper